Effect of Itraconazole on the Pharmacokinetics of Diclofenac in Beagle Dogs

Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Scientia Pharmaceutica 09/2010; 78(3):465-71. DOI: 10.3797/scipharm.1003-10
Source: PubMed


The objective of this study was to investigate the potential effect of itraconazole on the pharmacokinetics of diclofenac potassium in beagle dogs after oral coadministration. Five male beagle dogs received a single oral 50 mg dose of diclofenac potassium alone in phase I, and along with a single oral 100 mg dose of itraconazole in phase II. Blood samples obtained for 8.0 hours post dose were analysed for diclofenac concentration using a validated high performance liquid chromatography (HPLC) assay method. The area under plasma concentration-time curve (AUC(0ââ)), maximum plasma concentration (C(max)), time to reach C(max) (T(max)) and elimination half-life (t(1/2)), were calculated for diclofenac before and after itraconazole administration. The coadministration of itraconazole with diclofenac potassium has resulted in a significant reduction in AUC(0ââ) and C(max) of diclofenac, which was about 31 and 42%; respectively. No statistically significant differences were observed for T(max) and t(1/2) of diclofenac between the two phases. Therefore, it could be concluded that oral coadministration of itraconazole may have the potential to affect the absorption of diclofenac as indicated by the significant reduction in its AUC and C(max) in beagle dogs.

Full-text preview

Available from: PubMed Central
  • Source
    • "It is well known that top athletes widely use NSAIDs, to treat their sports injuries frequently diclofenac, in larger doses [13] that can result in significantly higher plasma and tissue levels. In an in vivo animal study, application of diclofenac in therapeutic doses resulted in higher plasma concentration: a single 50 mg oral dose of diclofenac led to 6 µg/mL (approximately 20 µM/L) peak plasma concentration in Beagle dogs [40]. In clinical settings, diclofenac plasma levels can be increased by dietary constituents (e.g. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present work was to characterize the electrophysiological effects of the non-steroidal anti-inflammatory drug diclofenac and to study the possible proarrhythmic potency of the drug in ventricular muscle. Ion currents were recorded using voltage clamp technique in canine single ventricular cells and action potentials were obtained from canine ventricular preparations using microelectrodes. The proarrhythmic potency of the drug was investigated in an anaesthetized rabbit proarrhythmia model. Action potentials were slightly lengthened in ventricular muscle but were shortened in Purkinje fibers by diclofenac (20 µM). The maximum upstroke velocity was decreased in both preparations. Larger repolarization prolongation was observed when repolarization reserve was impaired by previous BaCl(2) application. Diclofenac (3 mg/kg) did not prolong while dofetilide (25 µg/kg) significantly lengthened the QT(c) interval in anaesthetized rabbits. The addition of diclofenac following reduction of repolarization reserve by dofetilide further prolonged QT(c). Diclofenac alone did not induce Torsades de Pointes ventricular tachycardia (TdP) while TdP incidence following dofetilide was 20%. However, the combination of diclofenac and dofetilide significantly increased TdP incidence (62%). In single ventricular cells diclofenac (30 µM) decreased the amplitude of rapid (I(Kr)) and slow (I(Ks)) delayed rectifier currents thereby attenuating repolarization reserve. L-type calcium current (I(Ca)) was slightly diminished, but the transient outward (I(to)) and inward rectifier (I(K1)) potassium currents were not influenced. Diclofenac at therapeutic concentrations and even at high dose does not prolong repolarization markedly and does not increase the risk of arrhythmia in normal heart. However, high dose diclofenac treatment may lengthen repolarization and enhance proarrhythmic risk in hearts with reduced repolarization reserve.
    PLoS ONE 12/2012; 7(12):e53255. DOI:10.1371/journal.pone.0053255 · 3.23 Impact Factor